CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. Casolino R, Braconi C. J Hepatol 2021 Feb 18. pii: S0168-8278(21)00045.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Casolino R, Braconi C. CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. J Hepatol 2021 Feb 18. pii: S0168-8278(21)00045.
PMID: 33612309